Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6,682 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.6
Industry P/E
--
EV/EBITDA
-35.6
Div. Yield
0 %
Debt to Equity
--
Book Value
$22.7
EPS
$-2.3
Face value
--
Shares outstanding
39,339,960
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
| 6.2 | -10.7 | 6.2 | 161.3 | 78.4 | -- | -- |
|
BSE Sensex*
| -12.9 | -7.8 | -13.7 | -2.1 | 7.3 | 8.5 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
| 153.5 | 37.6 | 51.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
|
169.9 | 6,681.9 | 0.0 | -77.6 | -- | -16.9 | -- | 8.6 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 64.5 | 7,640.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.2 | 156.5 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product... candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. Read more
Chairman of the Board of Directors & CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Chairman of the Board of Directors & CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Belite Bio Inc ADR (BLTE) is $169.85 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Belite Bio Inc ADR (BLTE) has given a return of 78.43% in the last 3 years.
Since, TTM earnings of Belite Bio Inc ADR (BLTE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-70.08
|
7.06
|
|
2024
|
-54.12
|
13.41
|
|
2023
|
-39.05
|
13.66
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Belite Bio Inc ADR (BLTE) are Rs 200.00 and Rs 49.00 as of 06-Apr-2026.
Belite Bio Inc ADR (BLTE) has a market capitalisation of $ 6,682 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Belite Bio Inc ADR (BLTE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$2.60
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.